Valuation: Sera Prognostics, Inc.

Market Cap 80.08M 69.39M 65.48M 59.41M 111M 7.68B 112M 782M 301M 3.89B 301M 294M 12.38B P/E 2026 *
-3.09x
P/E 2027 * -3.79x
Enterprise Value 80.08M 69.39M 65.48M 59.41M 111M 7.68B 112M 782M 301M 3.89B 301M 294M 12.38B EV / Sales 2026 *
356x
EV / Sales 2027 * 41.6x
Free-Float
85.68%
Yield 2026 *
-
Yield 2027 * -
1 day-0.99%
Current month-5.19%
1 month+2.55%
3 months+9.24%
6 months-2.43%
Current year-31.86%
1 week 1.98
Extreme 1.98
2.06
1 month 1.92
Extreme 1.915
2.21
Current year 1.56
Extreme 1.56
3.85
1 year 1.56
Extreme 1.56
3.95
3 years 1.37
Extreme 1.37
12.36
5 years 1.1
Extreme 1.1
12.36
10 years 1.1
Extreme 1.1
15.5
Manager TitleAgeSince
Chief Executive Officer 52 31/05/2023
Director of Finance/CFO 47 30/08/2026
Chief Tech/Sci/R&D Officer - 31/12/2021
Director TitleAgeSince
Chairman 74 19/04/2011
Chairman 58 07/06/2023
Director/Board Member 59 31/10/2011
Date Insider Type Main position Quantity % Market Cap. Importance
10/09/26 Sell

Chief Executive Officer

-7,022 0.0182%
10/09/26 Sell

General Counsel

-2,190 0.0057%
10/09/26 Sell

Chief Technology Officer

-486 0.0013%
Change 5-day change 1-year change 3-year change Capi.($)
-0.99%0.00%-35.16%+18.24% 80.08M
+0.33%+1.54%+9.95%+13.68% 22.35B
-0.92%-3.70%+6.52% - 14.39B
+2.12%+0.95%+12.93%-20.59% 3.67B
+5.24%+6.40%+42.65%+39.23% 2.92B
+0.37%0.00%-15.40% - 2.1B
+0.59%-3.35%-25.51%-36.48% 2.02B
-0.06%-4.13%-9.12%+12.48% 1.55B
+0.50%+8.15%+61.35%+98.09% 1.41B
+0.56%-3.04%-27.09%+1.61% 1.28B
Average +0.76%-1.13%+2.11%+15.78% 5.18B
Weighted average by Cap. +0.37%-0.91%+8.49%+12.26%

Financials

2026 *2027 *
Net sales 225K 195K 184K 167K 313K 21.57M 315K 2.2M 847K 10.94M 845K 826K 34.78M 1.92M 1.67M 1.57M 1.43M 2.68M 185M 2.7M 18.8M 7.24M 93.6M 7.23M 7.07M 298M
Net income -33.93M -29.4M -27.75M -25.17M -47.22M -3.25B -47.56M -331M -128M -1.65B -127M -125M -5.25B -29.1M -25.22M -23.8M -21.59M -40.5M -2.79B -40.79M -284M -110M -1.41B -109M -107M -4.5B
Net Debt - -
Logo Sera Prognostics, Inc.
Sera Prognostics, Inc. is a women's health diagnostic company utilizing its proprietary proteomics and bioinformatics platform, and significant data resources to enhance maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. It has built a proteomics and bioinformatics platform to characterize the biology of pregnancy and to discover and validate key protein biomarkers found in blood that are accurate predictors of dynamic changes that occur during pregnancy. Its commercial product, the PreTRM test, is a validated, commercially available blood-based biomarker test to predict the risk of a premature delivery, also known as preterm birth. The PreTRM test is a non-invasive blood test given to a pregnant woman, carrying a single fetus, during weeks 18 through 20 of gestation that provides a prediction of the expectant mother’s risk of delivering spontaneously before 37 weeks’ gestation.
Employees
72
Date Price Change Volume
14/09/26 US$2.010 -0.99% 19,938
11/09/26 US$2.030 -0.98% 26,356
10/09/26 US$2.050 +2.50% 72,092
09/09/26 US$2.000 -0.50% 8,252
08/09/26 US$2.010 -0.50% 64,074
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
2.030USD
Average target price
5.500USD
Spread / Average Target
+170.94%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. SERA Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!